A. Gordon Tunstall Net Worth

The estimated Net Worth of Gordon Tunstall is at least $3.51 Million dollars as of 1 March 2022. Mr. Tunstall owns over 10,000 units of Tabula Rasa HealthCare Inc stock worth over $315,620 and over the last 21 years he sold TRHC stock worth over $2,651,660. In addition, he makes $541,500 as Lead Independent Director at Tabula Rasa HealthCare Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Tunstall TRHC stock SEC Form 4 insiders trading

A has made over 32 trades of the Tabula Rasa HealthCare Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of TRHC stock worth $55,000 on 1 March 2022.

The largest trade he's ever made was exercising 25,773 units of Tabula Rasa HealthCare Inc stock on 8 May 2017 worth over $40,206. On average, A trades about 2,200 units every 39 days since 2003. As of 1 March 2022 he still owns at least 30,059 units of Tabula Rasa HealthCare Inc stock.

You can see the complete history of Mr. Tunstall stock trades at the bottom of the page.

A. Gordon Tunstall biography

A. Gordon Tunstall CPA serves as Lead Independent Director of the Company. Mr. Tunstall founded Tunstall Consulting, Inc. in 1980, which provides entrepreneurs with advisory services developing growth capital in the institutional capital markets. Mr. Tunstall has served as director on several boards, including excelleRx, Inc., Kforce Inc., Health Insurance Innovations, Inc., Advanced Lighting Technologies, Inc., JLM Industries, Inc., Horizon Medical Products, Inc., Discount Auto Parts, Inc., L.A.T. Sportswear and OrthoSynetics, Inc. (formerly Orthodontic Centers of America, Inc.). Mr. Tunstall is a CPA. Mr. Tunstall attended Widener College and received a Bachelor of Science in accounting.

What is the salary of A Tunstall?

As the Lead Independent Director of Tabula Rasa HealthCare Inc, the total compensation of A Tunstall at Tabula Rasa HealthCare Inc is $541,500. There are 5 executives at Tabula Rasa HealthCare Inc getting paid more, with Calvin Knowlton having the highest compensation of $5,135,730.

How old is A Tunstall?

A Tunstall is 76, he's been the Lead Independent Director of Tabula Rasa HealthCare Inc since 2019. There are no older and 17 younger executives at Tabula Rasa HealthCare Inc.

What's A Tunstall's mailing address?

Gordon's mailing address filed with the SEC is 228 STRAWBRIDGE DRIVE, SUITE 100, MOORESTOWN, NJ, 08057.

Insiders trading at Tabula Rasa HealthCare Inc

Over the last 8 years, insiders at Tabula Rasa HealthCare Inc have traded over $245,667,405 worth of Tabula Rasa HealthCare Inc stock and bought 1,486,398 units worth $7,620,320 . The most active insiders traders include Calvin H Knowlton, Orsula V Knowlton, and Capital Management, L.P.Ic .... On average, Tabula Rasa HealthCare Inc executives and independent directors trade stock every 8 days with the average trade being worth of $441,116. The most recent stock trade was executed by Michael Greenhalgh on 28 June 2023, trading 25,000 units of TRHC stock currently worth $77,750.

What does Tabula Rasa HealthCare Inc do?

the tabula rasa healthcare family of companies provide new beginnings for our clients, through innovative service models and fresh approaches to healthcare technology. our leaders understand that to maximize patient experiences and outcomes, they must help providers to balance efficiency and scalability with safety and individualization of care.

Complete history of Mr. Tunstall stock trades at Health Insurance Innovations, Kforce, and Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare Inc executives and stock owners

Tabula Rasa HealthCare Inc executives and other stock owners filed with the SEC include:

• Calvin Knowlton,
  Chairman of the Board, Chief Executive Officer, Co-Founder
• Orsula Knowlton,
  President, Co-Founder, Chief Marketing Officer & New Business Development Officer, Director
• Brian Adams,
  Chief Financial Officer
• Pamela Schweitzer,
  Independent Director
• Dr. Calvin H. Knowlton BSc Pharm, MDiv, Ph.D.,
  Co-Founder, Chairman & CEO
• A. Gordon Tunstall,
  Lead Independent Director
• Dr. Orsula Voltis Knowlton BScPharm, M.B.A., MBA, Pharm.D., PharmD,
  Co-Founder, Pres, Chief Marketing & New Bus. Devel. Officer and Director
• Michael Greenhalgh,
  Chief Operating Officer
• Michael Purcell,
  Independent Director
• Samira Beckwith,
  Independent Director
• Dennis Helling,
  Independent Director
• Jan Berger,
  Independent Director
• Kathrine O'Brien,
  Independent Director
• Frank Sparacino,
  IR Contact Officer
• Jeffrey DiFrancesco,
  Chief Product Officer
• Bob Sullivan,
  Chief Technology Officer
• Steve Lemak,
  Senior Vice President - IT Infrastructure, CareVention HealthCare Division
• Michael Greenhalgh,
  Co-Founder, Chief Operating Officer
• Frank Sparacino C.F.A., CPA,
  Sr. VP of Investor Relations & Corp. Devel.
• Phillip W. Heath MS,
  Chief Admin. Officer
• Dr. Jacques Turgeon B.Pharm., Ph.D.,
  Chief Scientific Officer & CEO of TRHC Precision Pharmacotherapy, R&D Institute
• Joseph J. Filippoli,
  Chief Information Officer
• Bob Sullivan M.S.,
  Chief Technology Officer
• Andrea Carolan Speers M.S.,
  Corp. Controller & Chief Accounting Officer
• Bruce Luehrs,
  Director
• Venture Partners Iii, Llcra...,
  
• Eric R Arnson,
  10% owner
• Growth Fund 1 Q Lpbressner ...,
  
• Daniel C Lubin,
  Director
• Michael J Gausling,
  10% owner
• Glen R Bressner,
  Director
• Growth Fund 1 A Lpbressner ...,
  
• Joann M. Durham,
  10% owner
• John R. Durham,
  10% owner
• Growth Fund 1 A Lp Originat...,
  
• Stage2 Ventures, L.P.Stage2...,
  
• Growth Fund 1 Q Lp Originat...,
  
• Michael Anthony Bruno,
  CHIEF ACCOUNTING OFFICER
• Ronald Paul Mitchell,
  
• Thomas Cancro,
  CHIEF FINANCIAL OFFICER
• Richard W. Ii Rew,
  CHIEF LEGAL OFFICER, SECRETARY
• Jonathan David Schwartz,
  
• Capital Management, L.P.Ic ...,
  
• Capital Management, L.P.Ic ...,
  
• Capital Management, L.P.Ind...,